

Massimo Gadina

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1957065/massimo-gadina-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

103
papers

12,970
citations

49
h-index

113
g-index

115
ext. papers

15,899
ext. citations

14.2
avg, IF

6.23
L-index

#	Paper	IF	Citations
103	EAACI Biologicals Guidelines-dupilumab for children and adults with moderate-to-severe atopic dermatitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021 , 76, 988-1009	9.3	7
102	JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition. <i>Journal of Allergy and Clinical Immunology</i> , 2021 , 148, 911-925	11.5	5
101	Pleiotropic consequences of metabolic stress for the major histocompatibility complex class II molecule antigen processing and presentation machinery. <i>Immunity</i> , 2021 , 54, 721-736.e10	32.3	5
100	Homozygous variant p. Arg90His in NCF1 is associated with early-onset Interferonopathy: a case report. <i>Pediatric Rheumatology</i> , 2021 , 19, 54	3.5	3
99	JAK inhibitors: Ten years after. <i>European Journal of Immunology</i> , 2021 , 51, 1615-1627	6.1	13
98	JAK1: Number one in the family; number one in inflammation?. <i>Rheumatology</i> , 2021 , 60, ii3-ii10	3.9	3
97	Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. <i>Nature Communications</i> , 2021 , 12, 3391	17.4	19
96	A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?. <i>Arthritis and Rheumatology</i> , 2021 , 73, 2166-2178	9.5	9
95	3-hydroxy-L-kynurenamine is an immunomodulatory biogenic amine. <i>Nature Communications</i> , 2021 , 12, 4447	17.4	9
94	Granzyme A and CD160 expression delineates ILC1 with graded functions in the mouse liver. <i>European Journal of Immunology</i> , 2021 , 51, 2568-2575	6.1	6
93	Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1886-1895	9.5	24
92	Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies.. <i>Pharmaceuticals</i> , 2021 , 15,	5.2	2
91	HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19. <i>Science Immunology</i> , 2020 , 5,	2.8	66
90	SnapShot: Jak-STAT Signaling II. <i>Cell</i> , 2020 , 181, 1696-1696.e1	56.2	19
89	Tofacitinib inhibits the development of experimental autoimmune uveitis and reduces the proportions of Th1 but not of Th17 cells. <i>Molecular Vision</i> , 2020 , 26, 641-651	2.3	6
88	High throughput pSTAT signaling profiling by fluorescent cell barcoding and computational analysis. <i>Journal of Immunological Methods</i> , 2020 , 477, 112667	2.5	3
87	Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease. <i>Nature</i> , 2020 , 577, 103-108	50.4	110

86	Somatic Mutations in and Severe Adult-Onset Autoinflammatory Disease. <i>New England Journal of Medicine</i> , 2020 , 383, 2628-2638	59.2	160
85	Type 2 immunity in the skin and lungs. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020 , 75, 1582-1605	9.3	111
84	Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies. <i>Arthritis Research and Therapy</i> , 2020 , 22, 69	5.7	17
83	Translating JAKs to Jakinibs. <i>Journal of Immunology</i> , 2020 , 204, 2011-2020	5.3	13
82	Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	19
81	Janus kinases to jakinibs: from basic insights to clinical practice. <i>Rheumatology</i> , 2019 , 58, i4-i16	3.9	72
80	Second Case of HOIP Deficiency Expands Clinical Features and Defines Inflammatory Transcriptome Regulated by LUBAC. <i>Frontiers in Immunology</i> , 2019 , 10, 479	8.4	31
79	Cytokines and Cytokine Receptors 2019 , 127-155.e1		24
78	Protein Kinase Antagonists in Therapy of Immunological and Inflammatory Diseases 2019 , 1185-1196.e1		1
77	Transcriptional, Epigenetic and Pharmacological Control of JAK/STAT Pathway in NK Cells. <i>Frontiers in Immunology</i> , 2019 , 10, 2456	8.4	4
76	Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells. <i>JCI Insight</i> , 2019 , 4,	9.9	11
75	183 A phase 1B/2A trial of tofacitinib, an oral janus kinase inhibitor, in systemic lupus erythematosus 2019 ,		7
74	JAK Inhibition Differentially Affects NK Cell and ILC1 Homeostasis. <i>Frontiers in Immunology</i> , 2019 , 10, 2972	8.4	5
73	Selective Janus kinase inhibitors come of age. <i>Nature Reviews Rheumatology</i> , 2019 , 15, 74-75	8.1	40
72	Development of a Validated Interferon Score Using NanoString Technology. <i>Journal of Interferon and Cytokine Research</i> , 2018 , 38, 171-185	3.5	69
71	Germline gain-of-function myeloid differentiation primary response gene-88 (MYD88) mutation in a child with severe arthritis. <i>Journal of Allergy and Clinical Immunology</i> , 2018 , 141, 1943-1947.e9	11.5	9
70	Aberrant tRNA processing causes an autoinflammatory syndrome responsive to TNF inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 612-619	2.4	37
69	Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. <i>Journal of Leukocyte Biology</i> , 2018 , 104, 499-514	6.5	77

68	Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 364-373	6.1	57
67	JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. <i>Journal of Clinical Investigation</i> , 2018 , 128, 3041-3052	15.9	256
66	JAK/STAT signaling in regulation of innate lymphoid cells: The gods before the guardians. <i>Immunological Reviews</i> , 2018 , 286, 148-159	11.3	34
65	Cerebrospinal Fluid Cytokines Correlate With Aseptic Meningitis and Blood-Brain Barrier Function in Neonatal-Onset Multisystem Inflammatory Disease: Central Nervous System Biomarkers in Neonatal-Onset Multisystem Inflammatory Disease Correlate With Central Nervous System Inflammation. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1325-1336	9.5	31
64	JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. <i>Drugs</i> , 2017 , 77, 521-546	12.1	374
63	Dense genotyping of immune-related loci implicates host responses to microbial exposure in Behçet disease susceptibility. <i>Nature Genetics</i> , 2017 , 49, 438-443	36.3	89
62	Brief Report: Deficiency of Complement 1r Subcomponent in Early-Onset Systemic Lupus Erythematosus: The Role of Disease-Modifying Alleles in a Monogenic Disease. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1832-1839	9.5	22
61	JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. <i>Nature Reviews Drug Discovery</i> , 2017 , 16, 843-862	64.1	402
60	Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases. <i>Journal of Autoimmunity</i> , 2017 , 85, 20-31	15.5	49
59	Generation and differentiation of induced pluripotent stem cells reveal ankylosing spondylitis risk gene expression in bone progenitors. <i>Clinical Rheumatology</i> , 2017 , 36, 143-154	3.9	8
58	Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction. <i>Arthritis and Rheumatology</i> , 2017 , 69, 148-160	9.5	131
57	HiJAKing Innate Lymphoid Cells?. <i>Frontiers in Immunology</i> , 2017 , 8, 438	8.4	9
56	Targeting cytokine signaling in autoimmunity: back to the future and beyond. <i>Current Opinion in Immunology</i> , 2016 , 43, 89-97	7.8	35
55	Whole Chromosome Instability induces senescence and promotes SASP. <i>Scientific Reports</i> , 2016 , 6, 35218	4.9	77
54	Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. <i>Nature Reviews Rheumatology</i> , 2016 , 12, 25-36	8.1	347
53	Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. <i>Nature Genetics</i> , 2016 , 48, 67-73	36.3	359
52	Biallelic hypomorphic mutations in a linear deubiquitinase define otulipenia, an early-onset autoinflammatory disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 10127-32	11.5	150
51	The JAK-STAT pathway: impact on human disease and therapeutic intervention. <i>Annual Review of Medicine</i> , 2015 , 66, 311-28	17.4	713

50	Super-enhancers delineate disease-associated regulatory nodes in T cells. <i>Nature</i> , 2015 , 520, 558-62	50.4	247
49	Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. <i>Journal of Clinical Investigation</i> , 2015 , 125, 4196-211	15.9	181
48	Activated STING in a vascular and pulmonary syndrome. <i>New England Journal of Medicine</i> , 2014 , 371, 507-518	59.2	757
47	Early-onset stroke and vasculopathy associated with mutations in ADA2. <i>New England Journal of Medicine</i> , 2014 , 370, 911-20	59.2	485
46	A173: Cerebrospinal Fluid Cytokines Correlate With Innate Immune Cells in Neonatal Onset Multisystem Inflammatory Disease (NOMID) Patients in Clinical Remission Treated With Anakinra. <i>Arthritis and Rheumatology</i> , 2014 , 66, S226-S226	9.5	4
45	Advances in kinase inhibition: treating rheumatic diseases and beyond. <i>Current Opinion in Rheumatology</i> , 2014 , 26, 237-43	5.3	11
44	Reversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib. <i>Journal of Investigative Dermatology</i> , 2014 , 134, 992-1000	4.3	49
43	Jakpot! New small molecules in autoimmune and inflammatory diseases. <i>Experimental Dermatology</i> , 2014 , 23, 7-11	4	91
42	Janus kinases: an ideal target for the treatment of autoimmune diseases. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2013 , 16, S70-2	1.1	23
41	The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders. <i>BioDrugs</i> , 2013 , 27, 431-8	7.9	61
40	Cytokines and cytokine receptors 2013 , 108-135		5
39	Kinase inhibitors in the treatment of immune-mediated disease. <i>F1000 Medicine Reports</i> , 2012 , 4, 5		48
38	Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). <i>Journal of Immunology</i> , 2011 , 186, 4234-43	5.3	466
37	Cytokine signaling: birth of a pathway. <i>Journal of Immunology</i> , 2011 , 187, 5475-8	5.3	34
36	Accurate and simple measurement of the pro-inflammatory cytokine IL-1 β using a whole blood stimulation assay. <i>Journal of Visualized Experiments</i> , 2011 ,	1.6	4
35	A novel mutation of IL1RN in the deficiency of interleukin-1 receptor antagonist syndrome: description of two unrelated cases from Brazil. <i>Arthritis and Rheumatism</i> , 2011 , 63, 4007-17		77
34	Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. <i>Nature Genetics</i> , 2010 , 42, 698-702	36.3	475
33	USP17 regulates Ras activation and cell proliferation by blocking RCE1 activity. <i>Journal of Biological Chemistry</i> , 2009 , 284, 9587-95	5.4	65

32	Immune modulation: Turncoat regulatory T cells. <i>Nature Medicine</i> , 2009 , 15, 1365	50.5	4
31	An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. <i>New England Journal of Medicine</i> , 2009 , 360, 2426-37	59.2	726
30	Respiratory syncytial virus NS1 protein degrades STAT2 by using the Elongin-Cullin E3 ligase. <i>Journal of Virology</i> , 2007 , 81, 3428-36	6.6	138
29	Cytohesin binder and regulator augments T cell receptor-induced nuclear factor of activated T Cells.AP-1 activation through regulation of the JNK pathway. <i>Journal of Biological Chemistry</i> , 2006 , 281, 19985-94	5.4	12
28	Cytohesin binder and regulator (cybr) is not essential for T- and dendritic-cell activation and differentiation. <i>Molecular and Cellular Biology</i> , 2006 , 26, 6623-32	4.8	17
27	Immunodeficiency is a tough nut to CRAC: the importance of calcium flux in T cell activation. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2006 , 6, 253-6		8
26	CXCL12 signaling is independent of Jak2 and Jak3. <i>Journal of Biological Chemistry</i> , 2005 , 280, 17408-14	5.4	37
25	G(i)-protein-dependent inhibition of IL-12 production is mediated by activation of the phosphatidylinositol 3-kinase-protein 3 kinase B/Akt pathway and JNK. <i>Journal of Immunology</i> , 2005 , 175, 2994-9	5.3	89
24	Viral FLIP impairs survival of activated T cells and generation of CD8+ T cell memory. <i>Journal of Immunology</i> , 2004 , 172, 6313-23	5.3	43
23	Ubiquitination for activation: new directions in the NF-kappaB roadmap. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2004 , 4, 144-6		9
22	New interleukins: are there any more?. <i>Current Opinion in Infectious Diseases</i> , 2003 , 16, 211-7	5.4	11
21	Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. <i>Journal of Clinical Immunology</i> , 2003 , 23, 147-61	5.7	270
20	Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. <i>Oncogene</i> , 2002 , 21, 5097-107	9.2	122
19	Fyn kinase initiates complementary signals required for IgE-dependent mast cell degranulation. <i>Nature Immunology</i> , 2002 , 3, 741-8	19.1	394
18	Cybr, a cytokine-inducible protein that binds cytohesin-1 and regulates its activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 2625-9	11.5	36
17	STAT4 serine phosphorylation is critical for IL-12-induced IFN-gamma production but not for cell proliferation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 12281-6	11.5	149
16	Cytokines and their role in lymphoid development, differentiation and homeostasis. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2002 , 2, 495-506	3.3	73
15	Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. <i>Science</i> , 2002 , 297, 2063-6	33.3	409

14	Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. <i>Cell</i> , 2002 , 109 Suppl, S121-31	56.2	850
13	Signaling by type I and II cytokine receptors: ten years after. <i>Current Opinion in Immunology</i> , 2001 , 13, 363-73	7.8	165
12	Inducible expression of Stat4 in dendritic cells and macrophages and its critical role in innate and adaptive immune responses. <i>Journal of Immunology</i> , 2001 , 166, 4446-55	5.3	150
11	Role of cytokines in cancer cachexia in a murine model of intracerebral injection of human tumours. <i>Cytokine</i> , 2001 , 15, 27-38	4	28
10	Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases. <i>Molecular Cell</i> , 2001 , 8, 959-69	17.6	120
9	Cytokine regulation of IL-12 receptor beta2 expression: differential effects on human T and NK cells. <i>European Journal of Immunology</i> , 2000 , 30, 1364-74	6.1	54
8	Inhibition of Th1 immune response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced Stat4 phosphorylation in T lymphocytes. <i>Journal of Immunology</i> , 2000 , 164, 1768-74	5.3	196
7	Hierarchy of protein tyrosine kinases in interleukin-2 (IL-2) signaling: activation of syk depends on Jak3; however, neither Syk nor Lck is required for IL-2-mediated STAT activation. <i>Molecular and Cellular Biology</i> , 2000 , 20, 4371-80	4.8	35
6	IL-12 receptor beta 2 (IL-12R beta 2)-deficient mice are defective in IL-12-mediated signaling despite the presence of high affinity IL-12 binding sites. <i>Journal of Immunology</i> , 2000 , 165, 6221-8	5.3	137
5	The Docking Molecule Gab2 Is Induced by Lymphocyte Activation and Is Involved in Signaling by Interleukin-2 and Interleukin-15 but Not Other Common γ Chain-using Cytokines. <i>Journal of Biological Chemistry</i> , 2000 , 275, 26959-26966	5.4	74
4	Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. <i>Cell</i> , 1999 , 97, 133-44	56.2	1008
3	Preclinical evaluation of the ribosome-inactivating proteins PAP-1, PAP-S and RTA in mice. <i>International Journal of Immunopharmacology</i> , 1995 , 17, 829-39		12
2	A study of the intracellular routing of cytotoxic ribonucleases. <i>Journal of Biological Chemistry</i> , 1995 , 270, 17476-81	5.4	75
1	Differential sensitivity of in vivo TNF and IL-6 production to modulation by anti-inflammatory drugs in mice. <i>International Journal of Immunopharmacology</i> , 1992 , 14, 1045-50		45